Shortage of canine heartworm treatment to continue

12/4/2013 | Plain Dealer (Cleveland), The

Immiticide, the only FDA-approved treatment for canine heartworm disease, has been in short supply since 2009 regulatory changes complicated importation of an arsenic-based ingredient. Production problems at the Ohio plant exacerbated the issue, and now the plant is poised to close. For now, veterinarians can obtain the drug on a case-by-case basis, and FDA Center for Veterinary Medicine officials said this week that limited imports will continue. In the meantime, veterinarian Dave Koncal, president-elect of the Ohio Veterinary Medical Association, said the situation serves as an important reminder that owners should be vigilant about keeping dogs on heartworm prevention medication.

View Full Article in:

Plain Dealer (Cleveland), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY